Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  02:41 2022-10-03 pm EDT
9.810 USD   +2.51%
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ALX ONCOLOGY HOLDINGS INC.
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
08/15ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces the Sele..
CI
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/11ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponso..
CI
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
More most relevant news
All news about ALX ONCOLOGY HOLDINGS INC.
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
More news
News in other languages on ALX ONCOLOGY HOLDINGS INC.
08/16L'Evorpacept d'ALX Oncology choisi comme nouveau bras de traitement dans un essai sur l..
08/15ALX Oncology déclare qu'Evorpacept a été sélectionné dans un essai de stade précoce en ..
08/15ALX Oncology Holdings Inc. et Quantum Leap Healthcare Collaborative annoncent la sélect..
08/11Le premier patient reçoit une dose dans le cadre de l'essai de mi-étape d'ALX Oncology ..
08/11ALX Oncology Holdings Inc. annonce l'administration d'une dose à un premier patient dan..
08/08ALX Oncology Holdings Inc. annonce ses résultats pour le deuxième trimestre et le semes..
08/01ALX Oncology reçoit la désignation Fast-Track de la FDA pour son médicament contre le c..
08/01Evorpacept d'ALX Oncology reçoit la désignation Fast Track de la FDA comme traitement d..
06/29ALX Oncology obtient de la FDA la désignation de médicament orphelin pour Evorpacept
06/03ALX Oncology Holdings Inc annonce des mises à jour du programme clinique Evorpacept
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
08/09Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discoun..
MT
06/06Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Ra..
MT
05/19Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $48 From $70, Reiterates..
MT
More recommendations
Press releases
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
More press releases
Upcoming event on ALX ONCOLOGY HOLDINGS INC.